查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1529689

SGLT2抑制剂市场规模、份额、趋势分析报告：按药物、适应症、按分销管道、按地区、细分市场预测，2024-2030年

SGLT2 Inhibitors Market Size, Share & Trends Analysis Report By Drug (Jardiance, Farxiga, Inpefa, Invokana), By Indication (Diabetes, Cardiovascular), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 159 Pages | 商品交期: 2-10个工作天内

价格

SGLT2 抑制剂市场成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，SGLT2抑制剂的全球市场规模预计将达到294.3亿美元，预测期内复合年增长率为7.71%。

美国糖尿病协会 (ADA)、欧洲糖尿病研究学会 (EASD) 和欧洲心臟病学会 (ESC) 等领先医疗组织的建议和支持指南表明，钠-葡萄糖共同输送体2 (SGLT2) 的抑製作用超过了葡萄糖的抑製作用我支持医学。例如，2023年8月，欧洲心臟病学会（ESC）综合了2021年以来进行的近十多项新临床试验的结果，包括EMPEROR-Preserved、DELIVER、STRONG-HF和IRONMAN，宣布对心臟衰竭指南进行重点更新。 2023 年 ESC 大会上提出的更新指南引入了使用 SGLT2 抑制剂治疗射血分数轻度降低 (HFmrEF)心臟衰竭患者的新建议。

此外，未来几年需要透析的患者数量将会增加，这表明对 SGLT2 抑制剂等用于治疗 CKD 患者的药物的需求很高。 2023 年 11 月，NICE（国家健康与照护卓越研究所）发布了指引草案，建议慢性肾臟病(CKD) 患者使用Empagliflozin（一种 SGLT2 抑制剂）。Empagliflozin已被证明可以有效减缓肾衰竭的进展并降低心臟病和中风的风险。 NICE 建议向 CKD 各个阶段的患者提供这种治疗。此类药物监管机构的建议将在预测期内增加对药物的需求。

老年人更容易患第 2 型糖尿病和心臟衰竭，而药物对这些疾病非常有效。这些人口变化正在增加对 SGLT2 抑制剂等有效治疗药物的需求。 SGLT2 抑制剂可有效降低心血管和肾臟风险，尤其是老年人。这项优点使这些药物成为老年患者的首选。据世界卫生组织 (WHO) 称，到 2022 年，大约有 14 亿人年龄在 60 岁或以上，而 2020 年这一数字为 10 亿。此外，世界卫生组织预测老年人口将达21亿。因此，老年人口的增加预计将增加全球对 SGLT2 抑制剂的需求并推动市场成长。

患者和医疗保健专业人员对糖尿病的认识不断提高，以及 SGLT2 抑制剂在治疗中的重要性，有助于提高处方率。例如，2021年，世卫组织启动了全球糖尿病契约倡议，以提高意识并改善患者获得糖尿病药物的机会，包括 SGLT2 抑制剂和胰岛素。预计此类倡议将推动 SGLT2 抑制剂的采用，并在预测期内为市场带来新的机会。

SGLT2 抑制剂市场报告亮点

  • Jardiance（Empagliflozin）细分市场预计将在 2023 年占据市场主导地位，并在预测期内显着成长。这种增长是由于糖尿病、慢性肾臟病和心血管疾病的盛行率不断上升以及治疗药物的高需求。
  • 2023年，第2型糖尿病细分市场占据主导地位。这一优势是由于糖尿病盛行率不断上升、老年人口不断增加以及药物处方率不断增加。
  • 2023 年，医院药局领域将主导市场。这一优势是由于糖尿病、慢性肾臟病和心臟衰竭患者的诊断和治疗住院人数的增加。
  • 由于先进的医疗基础设施、目标疾病盛行率上升以及有利的法规环境等因素，北美在市场上占据主导地位。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章 SGLT2 抑制剂市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • SGLT2抑制剂市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • 管道分析
    • 目标人口分析

第四章 SGLT2抑制剂市场：依药物估算与趋势分析

  • 全球 SGLT2 抑制剂市场：按药物分類的仪表板
  • 全球SGLT2抑制剂市场：依药物波动分析
  • 全球 SGLT2 抑制剂市场：按药物分類的收益
  • Jardiance（Empagliflozin）
  • Farxiga（Dapagliflozin）
  • Invokana（Canagliflozin）
  • Impefa（索格列净）
  • Qtern（Dapagliflozin/沙格列汀）
  • 其他 SGLT2 抑制剂

第五章 SGLT2抑制剂市场：按适应症估算与趋势分析

  • 全球 SGLT2 抑制剂市场：按适应症分类的仪表板
  • 全球SGLT2抑制剂市场：按适应症的波动分析
  • 全球 SGLT2 抑制剂市场：按适应症分類的收益
  • 2型糖尿病
  • 心血管
  • 慢性肾臟病（CKD）
  • 其他的

第六章 SGLT2抑制剂市场：依通路估算与趋势分析

  • 全球 SGLT2 抑制剂市场：按分销管道分類的仪表板
  • 全球SGLT2抑制剂市场：依通路波动分析
  • 全球 SGLT2 抑制剂市场：按分销管道分類的收益
  • 医院药房
  • 零售药房
  • 网路药房

第七章 SGLT2抑制剂市场：按药物、适应症和分销管道分類的区域估计和趋势分析

  • 区域仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
    • 主要经销商及通路伙伴名单
    • 主要客户
    • 2023年主要企业市场占有率分析
    • Boehringer Ingelheim International GmbH.
    • AstraZeneca
    • Merck &Co., Inc.
    • Johnson &Johnson Services, Inc.（Janssen Pharmaceuticals, Inc.）
    • TheracosBio, LLC
    • Lexicon Pharmaceuticals, Inc.
    • Eli Lilly and Company
    • Bristol-Myers Squibb Company
    • Glenmark Pharmaceuticals Ltd
Product Code: GVR-4-68040-322-4

SGLT2 Inhibitors Market Growth & Trends:

The global SGLT2 inhibitors market size is anticipated to reach USD 29.43 billion by 2030 and is expected to expand at a CAGR of 7.71% during the forecast period, according to a new report by Grand View Research, Inc. The recommendations and supportive guidelines from major health organizations, such as the American Diabetes Association (ADA), the European Association of for the Study of Diabetes (EASD), the European Society of Cardiology (ESC), and others have endorsed sodium-glucose cotransporter-2 (SGLT2) inhibitors for them beyond glucose control. For instance, in August 2023, the European Society of Cardiology (ESC) has issued a focused update to their heart failure guidelines, integrating findings from nearly a dozen new clinical trials since 2021, such as EMPEROR-Preserved, DELIVER, STRONG-HF, and IRONMAN. Released at the ESC Congress 2023, the updated guidelines introduce new recommendations for the use of SGLT2 inhibitors in treating patients with heart failure with mildly reduced ejection fraction (HFmrEF).

In addition, the growing number of patients needing dialysis over the next few years showcased high demand of medicines such as SGLT2 inhibitors for treatment of CKD patients. In November 2023, the National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending the use of empagliflozin, an SGLT2 inhibitor, for patients with chronic kidney disease (CKD). Empagliflozin has demonstrated efficacy in slowing the progression to kidney failure and reducing the risk of heart attacks and strokes. NICE recommends making this treatment available to patients across all stages of CKD. Such recommendations from drug regulatory agencies are expected to boost demand for drugs during the forecast period.

The elder adults are more prone to type 2 diabetes and heart failure, conditions where drugs have shown substantial benefits. This demographic shift increases the demand for effective treatments such as SGLT2 inhibitors. SGLT2 inhibitors are beneficial in reducing cardiovascular and renal risks, which are particularly prevalent in the elderly. This advantage makes these medications a preferred choice for older patients. According to the World Health Organization (WHO), in 2022, around 1.4 billion people were aged 60 years and over, which was raised from 1 billion in 2020. In addition, WHO estimates that the elderly population is expected to reach 2.1 billion. Thus, rising geriatric population is expected to boost demand for SGLT2 inhibitors worldwide and drive market growth.

Increasing awareness of diabetes and significance of SGLT2 inhibitors in treatment among both patients and healthcare providers contribute to higher prescription rates. For instance, in 2021, the WHO launched initiative "Global Diabetes Compact" to raise awareness and improve patient access to diabetic medicine including SGLT2 inhibitors and insulin. Such initiatives are expected to boost adoption of SGLT2 inhibitors and open new opportunities in the market over the forecast period.

SGLT2 Inhibitors Market Report Highlights:

  • Jardiance (empagliflozin) segment dominated the market in 2023 and is anticipated to grow significantly over the forecast period. This growth is attributed due to increasing prevalence of diabetes, CKD, and cardiovascular conditions and high drug demand for treatment
  • Type 2 diabetes segment dominated the market in 2023. This dominance is attributed due to rising incidence of diabetes, increasing geriatric population, and increased prescription rate of drug
  • Hospital pharmacies segment dominated the market in 2023. This dominance is attributed due to increasing number hospitalization of diabetes, CKD, and heart failure patients for diagnosis and treatment
  • North America dominated the market owing to factors such as advanced healthcare infrastructure, rising prevalence of target diseases, and favorable regulatory environment

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug
    • 1.2.2. Indication
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug and Indication outlook
    • 2.2.2. Distribution Channel outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. SGLT2 Inhibitors Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of target disease
      • 3.2.1.2. Technological advancements in drug development
      • 3.2.1.3. Growing awareness and diagnosis
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of drug development
      • 3.2.2.2. Stringent regulatory policies for drug approval
  • 3.3. SGLT2 Inhibitors Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Target population analysis

Chapter 4. SGLT2 Inhibitors Market: Drug Estimates & Trend Analysis

  • 4.1. Global SGLT2 Inhibitors Market: Drug Dashboard
  • 4.2. Global SGLT2 Inhibitors Market: Drug Movement Analysis
  • 4.3. Global SGLT2 Inhibitors Market By Drug, Revenue
  • 4.4. Jardiance (empagliflozin)
    • 4.4.1. Jardiance (empagliflozin) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Farxiga (dapagliflozin)
    • 4.5.1. Farxiga (dapagliflozin) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Invokana (canagliflozin)
    • 4.6.1. Invokana (canagliflozin) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Inpefa (sotagliflozin)
    • 4.7.1. Inpefa (sotagliflozin) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Qtern (dapagliflozin/saxagliptin)
    • 4.8.1. Qtern (dapagliflozin/saxagliptin) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Other SGLT2 Inhibitors
    • 4.9.1. Other SGLT2 inhibitors market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. SGLT2 Inhibitors Market: Indication Estimates & Trend Analysis

  • 5.1. Global SGLT2 Inhibitors Market: Indication Dashboard
  • 5.2. Global SGLT2 Inhibitors Market: Indication Movement Analysis
  • 5.3. Global SGLT2 Inhibitors Market Estimates and Forecasts, By Indication, Revenue (USD Million)
  • 5.4. Type 2 Diabetes
    • 5.4.1. Type 2 diabetes market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Cardiovascular
    • 5.5.1. Cardiovascular market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Chronic Kidney Disease (CKD)
    • 5.6.1. Chronic kidney disease (CKD) market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. SGLT2 Inhibitors Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Global SGLT2 Inhibitors Market: Distribution Channel Dashboard
  • 6.2. Global SGLT2 Inhibitors Market: Distribution Channel Movement Analysis
  • 6.3. Global SGLT2 Inhibitors Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online pharmacies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. SGLT2 Inhibitors Market: Regional Estimates & Trend Analysis By Drug, Indication, and Distribution Channel

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. Boehringer Ingelheim International GmbH.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. AstraZeneca
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Merck & Co., Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.)
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. TheracosBio, LLC
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Lexicon Pharmaceuticals, Inc.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Eli Lilly and Company
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Bristol-Myers Squibb Company
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Glenmark Pharmaceuticals Ltd
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America SGLT2 Inhibitors market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 4 North America SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 5 North America SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 U.S. SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 7 U.S. SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 8 U.S. SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9 Canada SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 10 Canada SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 11 Canada SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12 Mexico SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 13 Mexico SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 14 Mexico SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 15 Europe SGLT2 Inhibitors market, by region, 2018 - 2030 (USD Million)
  • Table 16 Europe SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 17 Europe SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 18 Europe SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 19 Germany SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 20 Germany SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 21 Germany SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 22 UK SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 23 UK SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 24 UK SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 France SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 26 France SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 27 France SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 Italy SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 29 Italy SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 30 Italy SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 31 Spain SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 32 Spain SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 33 Spain SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Denmark SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 35 Denmark SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 36 Denmark SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 Sweden SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 38 Sweden SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 39 Sweden SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 40 Norway SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 41 Norway SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 42 Norway SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific SGLT2 Inhibitors market, by region, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 46 Aisa Pacific SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 47 China SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 48 China SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 49 China SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50 Japan SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 51 Japan SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 52 Japan SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53 India SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 54 India SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 55 India SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 56 South Korea SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 57 South Korea SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 58 South Korea SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 59 Australia SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 60 Australia SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 61 Australia SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62 Thailand SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 63 Thailand SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 64 Thailand SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 65 Latin America SGLT2 Inhibitors market, by region, 2018 - 2030 (USD Million)
  • Table 66 Latin America SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 67 Latin America SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 68 Latin America SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 69 Brazil SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 70 Brazil SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 71 Brazil SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 72 Argentina SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 73 Argentina SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 74 Argentina SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75 MEA SGLT2 Inhibitors market, by region, 2018 - 2030 (USD Million)
  • Table 76 MEA SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 77 MEA SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 78 MEA SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 79 South Africa SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 80 South Africa SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 81 South Africa SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 85 UAE SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 86 UAE SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 87 UAE SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 88 Kuwait SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 89 Kuwait SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 90 Kuwait SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 SGLT2 Inhibitors market: market outlook
  • Fig. 14 SGLT2 Inhibitors competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 SGLT2 Inhibitors market driver impact
  • Fig. 18 SGLT2 Inhibitors market restraint impact
  • Fig. 19 SGLT2 Inhibitors market: Drug movement analysis
  • Fig. 20 SGLT2 Inhibitors market: Drug outlook and key takeaways
  • Fig. 21 Jardiance (empagliflozin) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Farxiga (dapagliflozin) estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Steglatro (ertugliflozin) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Invokana (canagliflozin) estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Brenzavvy (bexagliflozin) estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Inpefa (sotagliflozin) estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Other SGLT2 inhibitors estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 SGLT2 Inhibitors market: Indication movement analysis
  • Fig. 29 SGLT2 Inhibitors market: Indication outlook and key takeaways
  • Fig. 30 Type 2 diabetes market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Cardiovascular market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Chronic kidney disease (CKD) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 SGLT2 Inhibitors market: Distribution channel movement analysis
  • Fig. 35 SGLT2 Inhibitors market: Distribution channel outlook and key takeaways
  • Fig. 36 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Global SGLT2 Inhibitors market: Regional movement analysis
  • Fig. 40 Global SGLT2 Inhibitors market: Regional outlook and key takeaways
  • Fig. 41 Global SGLT2 Inhibitors market share and leading players
  • Fig. 42 North America, by country
  • Fig. 43 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. key country dynamics
  • Fig. 45 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Canada key country dynamics
  • Fig. 47 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Mexico key country dynamics
  • Fig. 49 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 UK key country dynamics
  • Fig. 52 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Germany key country dynamics
  • Fig. 54 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 France key country dynamics
  • Fig. 56 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Italy key country dynamics
  • Fig. 58 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Spain key country dynamics
  • Fig. 60 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Denmark key country dynamics
  • Fig. 62 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Sweden key country dynamics
  • Fig. 64 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Norway key country dynamics
  • Fig. 66 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 China key country dynamics
  • Fig. 69 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Japan key country dynamics
  • Fig. 71 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 India key country dynamics
  • Fig. 73 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Thailand key country dynamics
  • Fig. 75 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 South Korea key country dynamics
  • Fig. 77 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Australia key country dynamics
  • Fig. 79 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Brazil key country dynamics
  • Fig. 82 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Argentina key country dynamics
  • Fig. 84 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 South Africa key country dynamics
  • Fig. 87 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Saudi Arabia key country dynamics
  • Fig. 89 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 UAE key country dynamics
  • Fig. 91 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Kuwait key country dynamics
  • Fig. 93 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Market share of key market players - SGLT2 Inhibitors market